Coya Therapeutics (NASDAQ:COYA – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at Chardan Capital in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $14.00 price target on the stock. Chardan Capital’s price target would suggest a potential upside of 186.59% from the stock’s previous close.
Several other analysts have also issued reports on the company. D. Boral Capital restated a “buy” rating and issued a $15.00 target price on shares of Coya Therapeutics in a research note on Friday, April 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Monday, April 20th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research report on Monday, March 23rd. Wall Street Zen cut Coya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Roth Mkm began coverage on Coya Therapeutics in a research report on Friday, June 5th. They issued a “buy” rating and a $12.00 price target for the company. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.33.
Check Out Our Latest Stock Analysis on COYA
Coya Therapeutics Price Performance
Coya Therapeutics (NASDAQ:COYA – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.07. The firm had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.15 million. Coya Therapeutics had a negative return on equity of 55.86% and a negative net margin of 266.10%. As a group, research analysts expect that Coya Therapeutics will post -1.49 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Coya Therapeutics
Several hedge funds have recently made changes to their positions in the stock. Prosperity Wealth Management Inc. grew its position in shares of Coya Therapeutics by 16.4% in the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after purchasing an additional 3,350 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in Coya Therapeutics during the third quarter worth about $28,000. Cetera Investment Advisers grew its position in Coya Therapeutics by 36.4% during the first quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock worth $118,000 after buying an additional 8,000 shares in the last quarter. CIBC Private Wealth Group LLC purchased a new position in Coya Therapeutics during the fourth quarter worth about $47,000. Finally, Occudo Quantitative Strategies LP purchased a new position in Coya Therapeutics during the fourth quarter worth about $66,000. 39.75% of the stock is currently owned by hedge funds and other institutional investors.
Coya Therapeutics Company Profile
Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.
Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.
Featured Stories
- Five stocks we like better than Coya Therapeutics
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
- ERock IPO: A $1.3B Power Play Solution
- The AI Boom Has a Hidden Winner—And It’s Not Nvidia
- SMX: Can Molecular Tracking Technology Become the Next Moonshot?
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
